Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
Sanjay Chabra, B J Gill, Gaia Gallo, Danting Zhu, Celine Pitou, Christopher D Payne, Ana Accioly, Luis Puig, Sanjay Chabra, B J Gill, Gaia Gallo, Danting Zhu, Celine Pitou, Christopher D Payne, Ana Accioly, Luis Puig
Abstract
Introduction: Subcutaneous (SC) injection is a common route of drug administration; however, injection site pain (ISP) might create a negative patient experience. We evaluated ISP, bioequivalence, and overall safety of the citrate-free (CF) formulation of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A.
Methods: Two phase 1, single-blind studies were conducted in healthy participants. The crossover study A (NCT03848403) evaluated pain intensity on injection as measured by visual analog scale of pain (VAS) scores. Subjects (N = 70) were randomized 1:1:1 at the beginning to three possible treatment sequences and received a 1 mL SC injection of the three formulations sequentially in the abdomen on days 1, 8, and 15, respectively. A mixed-effects repeated measures analysis model was used to analyze VAS score by time post-injection. Study B (NCT04259346) evaluated the bioequivalence of a single 80 mg dose of CF formulation compared to the original commercial formulation. Subjects (N = 245) were randomized 1:1 to either commercial or CF formulation and received a single SC injection into the abdomen, arm, or thigh.
Results: Primary endpoint was achieved in both studies. In study A, least-squares mean (LSM) difference of VAS scores immediately post injection between commercial (n = 61) and CF formulation (n = 63) was - 21.7 (p < 0.0001), indicating a lower degree of pain associated with CF formulation. In study B, bioequivalence of the CF formulation was established as 90% CIs for the ratio of geometric LSM AUC0-tlast, AUC0-∞, and Cmax between treatments were contained within the prespecified limits of 0.8 and 1.25. Except for less ISP in the CF formulation, overall safety profile was comparable.
Conclusion: Ixekizumab CF formulation proved to be bioequivalent, was associated with less ISP, and had no other notable differences in the safety profile compared to the original commercial formulation.
Trail registration: ClinicalTrials.gov identifier NCT03848403, NCT04259346.
Keywords: Bioequivalence; Citrate-free; Injection site pain; Ixekizumab.
© 2022. The Author(s).
Figures
References
- Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986–2996. doi: 10.1007/s12325-019-01101-6.
- Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014;16(10):971–976. doi: 10.1111/dom.12304.
- Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol. 2006;98(2):218–221. doi: 10.1111/j.1742-7843.2006.pto_271.x.
- Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol. 1998;49(1):41–44.
- St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7(4):741–757. doi: 10.1007/s40744-020-00245-0.
- Zijlstra E, Jahnke J, Fischer A, Kapitza C, Forst T. Impact of injection speed, volume, and site on pain sensation. J Diabetes Sci Technol. 2018;12(1):163–168. doi: 10.1177/1932296817735121.
- Tangen LF, Lundbom JS, Skarsvåg TI, et al. The influence of injection speed on pain during injection of local anaesthetic. J Plast Surg Hand Surg. 2016;50(1):7–9. doi: 10.3109/2000656X.2015.1058269.
- Company ELa. Taltz® prescribing information. . Published 2020. Updated 06/2021. Accessed 16 Sep 2021.
- Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford) 2020;59(12):3834–3844. doi: 10.1093/rheumatology/keaa189.
- Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14(7):798–804. doi: 10.1111/j.1365-2702.2005.01121.x.
- Gely C, Marín L, Gordillo J, et al. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol. 2020;43(1):9–13. doi: 10.1016/j.gastrohep.2019.06.008.
- Yoshida T, Otaki Y, Katsuyama N, Seki M, Kubota J. New adalimumab formulation associated with less injection site pain and improved motivation for treatment. Mod Rheumatol. 2019;29(6):949–953. doi: 10.1080/14397595.2018.1520426.
- Cohen S, Samad A, Karis E, et al. Decreased injection site pain associated with phosphate-free etanercept formulation in rheumatoid arthritis or psoriatic arthritis patients: a randomized controlled trial. Rheumatol Ther. 2019;6(2):245–254. doi: 10.1007/s40744-019-0152-8.
- Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257–270. doi: 10.1007/s40744-016-0041-3.
- Bergman M, Patel P, Chen N, Jing Y, Saffore CD. Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States. Rheumatol Ther. 2021;8(1):109–118. doi: 10.1007/s40744-020-00256-x.
Source: PubMed